News | September 23, 2008

Bracco, Lantheus Partner to Promote CardioGen 82 for PET Perfusion Imaging

September 24, 2008 - Bracco Diagnostics Inc. and Lantheus Medical Imaging Inc. said yesterday they entered into an agreement for Lantheus to co-promote Bracco’s CardioGen-82 (Rubidium Rb 82 Generator), a myocardial perfusion positron emission tomography (PET) imaging agent.

CardioGen-82 is the only generator-based PET perfusion agent approved by the FDA and reimbursed for the evaluation of coronary artery disease (CAD).

CardioGen-82 was approved by the FDA in 1989 and has been used in hundreds of thousands of patients since then. CardioGen-82 PET myocardial perfusion imaging (MPI) has experienced double digit year-over-year growth since 2003. The companies said the agreement will further accelerate the rapid expansion of this modality.

“In seeking a partner to help us maximize the availability of CardioGen-82 to physicians whose patients may benefit from this PET imaging agent, we sought a company with vast experience in the myocardial perfusion imaging market and an extensive and knowledgeable sales force,” said Carlo Medici, president and CEO of Bracco Diagnostics Inc. “Lantheus Medical Imaging stood out as a company extremely well-suited for a partnership of this kind and we expect that this collaboration will quickly increase access to CardioGen-82.”

For more information: www.lantheus.com


Additional Content

News | PET Imaging

Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its ...

Home November 17, 2025
Home
News | PET Imaging

Sept. 18, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Society of Nuclear Cardiology ...

Home September 22, 2025
Home
News | PET Imaging

Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of ...

Home September 08, 2025
Home
News | PET Imaging

July 21, 2025 — Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart ...

Home July 22, 2025
Home
News | PET Imaging

Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose ...

Home March 03, 2025
Home
Subscribe Now